Your browser doesn't support javascript.
loading
Experimental acoustic characterization of an endoskeletal antibubble contrast agent: First results.
Panfilova, Anastasiia; Chen, Peiran; van Sloun, Ruud J G; Wijkstra, Hessel; Postema, Michiel; Poortinga, Albert T; Mischi, Massimo.
Afiliação
  • Panfilova A; Electrical Engineering Department, Faculty of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • Chen P; Electrical Engineering Department, Faculty of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • van Sloun RJG; Electrical Engineering Department, Faculty of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • Wijkstra H; Electrical Engineering Department, Faculty of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • Postema M; Department of Urology, Amsterdam University Medical Centers location AMC, Amsterdam, The Netherlands.
  • Poortinga AT; School of Electrical and Information Engineering, University of the Witwatersrand, Johannesburg, Braamfontein, South Africa.
  • Mischi M; BioMediTech, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Med Phys ; 48(11): 6765-6780, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34580883
ABSTRACT

PURPOSE:

An antibubble is an encapsulated gas bubble with an incompressible inclusion inside the gas phase. Current-generation ultrasound contrast agents are bubble-based they contain encapsulated gas bubbles with no inclusions. The objective of this work is to determine the linear and nonlinear responses of an antibubble contrast agent in comparison to two bubble-based ultrasound contrast agents, that is, reference bubbles and SonoVue TM .

METHODS:

Side scatter and attenuation of the three contrast agents were measured, using single-element ultrasound transducers, operating at 1.0, 2.25, and 3.5 MHz. The scatter measurements were performed at acoustic pressures of 200 and 300 kPa for 1.0 MHz, 300 kPa, and 450 kPa for 2.25 MHz, and 370 and 560 kPa for 3.5 MHz. Attenuation measurements were conducted at pressures of 13, 55, and 50 kPa for 1.0, 2.25, and 3.5 MHz, respectively. In addition, a dynamic contrast-enhanced ultrasound measurement was performed, imaging the contrast agent flow through a vascular phantom with a commercial diagnostic linear array probe.

RESULTS:

Antibubbles generated equivalent or stronger harmonic signal, compared to bubble-based ultrasound contrast agents. The second harmonic side-scatter amplitude of the antibubble agent was up to 3 dB greater than that of reference bubble agent and up to 4 dB greater than that of SonoVue TM at the estimated concentration of 8 × 10 4 bubbles/mL. For ultrasound with a center transmit frequency of 1.0 MHz, the attenuation coefficient of the antibubble agent was 8.7 dB/cm, whereas the attenuation coefficient of the reference agent was 7.7 and 0.3 dB/cm for SonoVue TM . At 2.25 MHz, the attenuation coefficients were 9.7, 3.0, and 0.6 dB/cm, respectively. For 3.5 MHz, they were 4.4, 1.8, and 1.0 dB/cm, respectively. A dynamic contrast-enhanced ultrasound recording showed the nonlinear signal of the antibubble agent to be 31% greater than for reference bubbles and 23% lower than SonoVue TM at a high concentration of 2 × 10 6 bubbles/mL.

CONCLUSION:

Endoskeletal antibubbles generate comparable or greater higher harmonics than reference bubbles and SonoVue TM . As a result, antibubbles with liquid therapeutic agents inside the gas phase have high potential to become a traceable therapeutic agent.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acústica / Meios de Contraste Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acústica / Meios de Contraste Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article